Douglas E. Williams

Douglas E. Williams, Ph.D., is currently the CEO and a Board member at TriArm Therapeutics, a company focused on CAR T-cell therapy. Previously, he held the position of President of Research and Development at Sana Biotechnology. Before that, he served as CEO of Codiak BioSciences and was Executive Vice President, Research and Development, at Biogen from January 2011 to July 2015. Dr. Williams transitioned to Biogen after his tenure at ZymoGenetics, where he was CEO and member of the Board of Directors, enabling their acquisition by Bristol Myers Squibb for $985 million.   He has also held a variety of leadership positions within the biotechnology industry. These include Chief Scientific Officer and Executive Vice President of Research and Development at Seattle Genetics, Senior Vice President and Washington Site Leader at Amgen and Executive Vice President and Chief Technology Officer and a member of the Board of Directors at Immunex. During his 30+ year career in the biotechnology industry, he has played a role in the development of several novel drugs including Enbrel, Tecfidera, and Spinraza. Dr. Williams has served as a board member of numerous biotechnology companies and is currently Chair of the Board of AC Immune SA.